Somatostatinrezeptor-PET
暂无分享,去创建一个
[1] H. Amthauer,et al. Somatostatinrezeptor-PET/CT , 2018, Nuklearmedizin.
[2] G. Karanikas,et al. Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors , 2017, Clinical nuclear medicine.
[3] W. Oyen,et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[4] Gerald Antoch,et al. Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT , 2017, European Radiology.
[5] V. Ambrosini,et al. The Impact of Somatostatin Receptor–Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis , 2017, The Journal of Nuclear Medicine.
[6] P. Herscovitch,et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] F. Beuschlein,et al. Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT. , 2013, Radiology.
[8] G. Schmidt,et al. The Role of 68Ga-DOTATATE PET/CT in Suspected Neuroendocrine Tumors , 2012, The Journal of Nuclear Medicine.
[9] A. Scarpa,et al. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. , 2012, European journal of cancer.
[10] E. Demirci,et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[11] C. Boy,et al. 68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors , 2011, The Journal of Nuclear Medicine.
[12] P. Cumming,et al. Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors , 2011, The Journal of Nuclear Medicine.
[13] H. Amthauer,et al. 68Ga-DOTATOC PET/CT of Neuroendocrine Tumors: Spotlight on the CT Phases of a Triple-Phase Protocol , 2011, The Journal of Nuclear Medicine.
[14] P. Cumming,et al. 68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor–Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors , 2010, The Journal of Nuclear Medicine.
[15] I. Kayani,et al. The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy , 2010, Journal of Nuclear Medicine.
[16] R. Bale,et al. 68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor–Mediated Radionuclide Therapy , 2009, Journal of Nuclear Medicine.
[17] B. Skogseid,et al. Elevated Plasma Chromogranin A Is the First Indication of Recurrence in Radically Operated Midgut Carcinoid Tumors , 2009, Neuroendocrinology.
[18] Manal M. Hassan,et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] E. Krenning,et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] O. Schillaci. Somatostatin Receptor Imaging in Patients with Neuroendocrine Tumors: Not Only SPECT? , 2007, Journal of Nuclear Medicine.
[21] Judit Erchegyi,et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors , 2006, Proceedings of the National Academy of Sciences.
[22] I. Modlin,et al. A 5‐decade analysis of 13,715 carcinoid tumors , 2003, Cancer.
[23] A. Haug,et al. Impact of 68Ga-DOTATATE PET/CT on the Surgical Management of Primary Neuroendocrine Tumors of the Pancreas or Ileum , 2014, Annals of Surgical Oncology.
[24] A. Haug,et al. Treatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: prognostic stratification with Ga-68-DOTA-TATE positron emission tomography. , 2014, Molecular imaging.
[25] V. Ambrosini,et al. Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[26] R. Bale,et al. Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007 .